Our vision is to become a leader in healthcare. We realize that our technology, intellectual property coverage and development capabilities have broader application.

The main areas of potential partner opportunities, which we have identified and where we have initial feasibility results are in the broad categories of:

:::	Nanotechnology
:::	Embolotherapy
:::	Tissue Bulking Agents
:::	Spray Hydrogel Wound Dressings
:::	Targeted Drug Delivery (Growth Factors and Nitric Oxide for wound healing or restenosis)
:::	Tissue Scaffolds
:::	Coatings

BioCure's ongoing research is directed in part to refinement of our nanotechnology franchise as well as innovation in support of our participation in spine/orthopedic, embolotherapy and woundcare programs. In addition, BioCure has conducted initial evaluation of using our PVA based fast crosslinking hydrogels for other applications. BioCure is interested in licensing these non-embolic products or finding partners for joint development or sponsored development.

As a result of its license agreement with CIBA Vision and CRCERT, BioCure has access to a variety of other technologies that we are not presently using in our research programs, that are available for licensing, joint ventures, or sponsored development.

Please contact us if you have any questions. We'd be happy to provide you with more information.